The advantages of new preparation production are obvious. Green leaf pharmaceutical has a stable layout

[enterprise news of China Pharmaceutical network] as a listed company of paclitaxel liposomes, LVYE pharmaceutical is expected to list a number of liposome and microsphere products This can be analyzed from these three points Firstly, lipusu is a paclitaxel liposome on the market all over the world; secondly, a microsphere R & D platform is established, and many products are under research; later, it actively expands the overseas market, risperidone microsphere has entered the NDA stage without further clinical certification by FDA New dosage form is an important direction of drug research and development in the future, and the market share of some listed products is no less than that of new molecular drugs At present, although there are generation differences in the development of new preparations at home and abroad, the national policy actively encourages the development of new preparations through priority review and other ways There are three distribution directions of new heavy-duty preparations in domestic enterprises, namely, long-acting protein drugs, antibody drug fusion products and carrier drugs Through the analysis of companies with new pharmaceutical products and R & D layout, without considering other achievements, only from the perspective of new pharmaceutical products and R & D layout, LVYE pharmaceutical is an enterprise worthy of attention and investment The new preparation is committed to the development of long-term, production advantages are obvious Many microsphere products (risperidone microsphere, triptorelin microsphere) of green leaf pharmaceutical are developed, and many products are approved for overseas clinical use Risperidone microsphere is approved by FDA without further clinical use, and it is already in the NDA stage In the future, it is expected to achieve the advantages of R & D and production through the creation of microsphere platform 1 Triptorelin microspheres will be listed in three years In 2016, the global market of triptorelin microspheres will be about 600 million US dollars, and the domestic market will be about 300 million RMB It accounts for nearly 70% of triptorelin's overall market At present, triptorelin microspheres are imported products in the domestic market, among which green leaf Pharmaceutical Co., Ltd is one of the research companies in China, but it has been approved for clinical application, and it is expected that the domestic products will be listed three years later 2 Risperidone microspheres are in the position of domestic R & D progress In 2016, the global market of risperidone microspheres was $900 million, and the domestic market was not opened In this research and development field, green leaf pharmaceutical has made progress in domestic pharmaceutical enterprises The clinical trial of chlorpromazine microsphere injection has been completed in China, and it was declared through FDA 505 (b) (2) in October 2015 The key clinical trial involving 108 patients in the United States is enough to support ly03004 to submit new drug listing application (NDA) in the United States through 505 (b) (2), and no further human clinical research is needed 3 Lipin is a paclitaxel liposome product in the world Lipin uses natural lecithin and cholesterol as the main excipients to pack paclitaxel in the liposome bilayer It was listed in 2003 It is the core product of green leaf pharmaceutical anti-tumor drugs and also a paclitaxel liposome product in the world At present, there is only one green leaf manufacturer As a listed company of paclitaxel liposomes, many liposome and microsphere products are expected to be listed This can be analyzed from these three aspects: 1 Lipuzu - paclitaxel liposomes on the global market Green leaf pharmaceutical is a global listed taxol liposome variety In 2016, the sales volume of PDB sample market reached 1 billion yuan, and it is expected to maintain a growth rate of more than 10% in 2017 Domestic paclitaxel albumin is expected to be approved in 2018, which may exert some pressure on liputian, but we believe that domestic paclitaxel albumin will replace imported varieties in the short term, and the short-term impact on liputian will not be great 2 Establish a microsphere R & D platform, with multiple products under research LVYE pharmaceutical has established long-term and sustained-release technology platform (focusing on the innovation of microsphere and nano particle technology), liposome and targeted drug delivery technology platform (the innovation of targeted drug delivery technology and liposome technology) to play the advantages of platform integration At present, there are many liposome microsphere products under research, among which vincristine sulfate liposome is in clinical stage III 3 Actively expand the overseas market, risperidone microspheres have entered the NDA stage without further clinical certification by FDA At present, LVYE pharmaceutical has 7 products under research overseas (including the United States, the European Union and Japan), including 4 innovative products developed in the United States Risperidone microspheres have completed all clinical data and entered the NDA stage It is expected to go on the market in 2018, and the other three products are also expected to go on the market before 2022 According to BCG's forecast, in 2022, four products will bring about $600 million in revenue to the company The national policy encourages the development of innovative preparations and the scientific research strength of LVYE pharmaceutical, which makes it in the front of many pharmaceutical enterprises, which is of great significance to the development of LVYE pharmaceutical enterprises and the national pharmaceutical industry From the perspective of investors, pharmaceutical enterprises with product strength and enterprise strength are worthy of attention Original title: innovative preparations, new drugs, rapid development, green leaf pharmaceutical layout stable